276 related articles for article (PubMed ID: 34728593)
1. A Review of the Role of Hypoxia in Radioresistance in Cancer Therapy.
Bouleftour W; Rowinski E; Louati S; Sotton S; Wozny AS; Moreno-Acosta P; Mery B; Rodriguez-Lafrasse C; Magne N
Med Sci Monit; 2021 Nov; 27():e934116. PubMed ID: 34728593
[TBL] [Abstract][Full Text] [Related]
2. Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia.
Marie-Egyptienne DT; Lohse I; Hill RP
Cancer Lett; 2013 Nov; 341(1):63-72. PubMed ID: 23200673
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia in Solid Tumors: How Low Oxygenation Impacts the "Six Rs" of Radiotherapy.
Rakotomalala A; Escande A; Furlan A; Meignan S; Lartigau E
Front Endocrinol (Lausanne); 2021; 12():742215. PubMed ID: 34539584
[TBL] [Abstract][Full Text] [Related]
4. Caveolin-1: a novel prognostic biomarker of radioresistance in cancer.
Mahmood J; Zaveri SR; Murti SC; Alexander AA; Connors CQ; Shukla HD; Vujaskovic Z
Int J Radiat Biol; 2016 Dec; 92(12):747-753. PubMed ID: 27623870
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia as a biomarker for radioresistant cancer stem cells.
Peitzsch C; Perrin R; Hill RP; Dubrovska A; Kurth I
Int J Radiat Biol; 2014 Aug; 90(8):636-52. PubMed ID: 24844374
[TBL] [Abstract][Full Text] [Related]
6. CSC Radioresistance: A Therapeutic Challenge to Improve Radiotherapy Effectiveness in Cancer.
Olivares-Urbano MA; Griñán-Lisón C; Marchal JA; Núñez MI
Cells; 2020 Jul; 9(7):. PubMed ID: 32660072
[TBL] [Abstract][Full Text] [Related]
7. Cancer stem cells and signaling pathways in radioresistance.
Chang L; Graham P; Hao J; Ni J; Deng J; Bucci J; Malouf D; Gillatt D; Li Y
Oncotarget; 2016 Mar; 7(10):11002-17. PubMed ID: 26716904
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia and anemia: effects on tumor biology and treatment resistance.
Vaupel P; Mayer A
Transfus Clin Biol; 2005 Feb; 12(1):5-10. PubMed ID: 15814285
[TBL] [Abstract][Full Text] [Related]
9. How can we overcome tumor hypoxia in radiation therapy?
Harada H
J Radiat Res; 2011; 52(5):545-56. PubMed ID: 21952313
[TBL] [Abstract][Full Text] [Related]
10. NADPH oxidase subunit 4 mediates cycling hypoxia-promoted radiation resistance in glioblastoma multiforme.
Hsieh CH; Wu CP; Lee HT; Liang JA; Yu CY; Lin YJ
Free Radic Biol Med; 2012 Aug; 53(4):649-58. PubMed ID: 22713363
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia, metabolism, and the circadian clock: new links to overcome radiation resistance in high-grade gliomas.
Shen H; Cook K; Gee HE; Hau E
J Exp Clin Cancer Res; 2020 Jul; 39(1):129. PubMed ID: 32631383
[TBL] [Abstract][Full Text] [Related]
12. Polyoxometalate-Based Radiosensitization Platform for Treating Hypoxic Tumors by Attenuating Radioresistance and Enhancing Radiation Response.
Yong Y; Zhang C; Gu Z; Du J; Guo Z; Dong X; Xie J; Zhang G; Liu X; Zhao Y
ACS Nano; 2017 Jul; 11(7):7164-7176. PubMed ID: 28640996
[TBL] [Abstract][Full Text] [Related]
13. The Critical Role of Hypoxic Microenvironment and Epigenetic Deregulation in Esophageal Cancer Radioresistance.
Macedo-Silva C; Miranda-Gonçalves V; Henrique R; Jerónimo C; Bravo I
Genes (Basel); 2019 Nov; 10(11):. PubMed ID: 31739546
[TBL] [Abstract][Full Text] [Related]
14. Targeting SLC25A10 alleviates improved antioxidant capacity and associated radioresistance of cancer cells induced by chronic-cycling hypoxia.
Hlouschek J; Ritter V; Wirsdörfer F; Klein D; Jendrossek V; Matschke J
Cancer Lett; 2018 Dec; 439():24-38. PubMed ID: 30205167
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of hypoxia-inducible factor-2 involved in chemo/radioresistance in solid tumors.
Zhao J; Du F; Luo Y; Shen G; Zheng F; Xu B
Cancer Treat Rev; 2015 Jul; 41(7):623-33. PubMed ID: 25981453
[TBL] [Abstract][Full Text] [Related]
16. Hypoxic tumor microenvironment: Implications for cancer therapy.
Roy S; Kumaravel S; Sharma A; Duran CL; Bayless KJ; Chakraborty S
Exp Biol Med (Maywood); 2020 Jul; 245(13):1073-1086. PubMed ID: 32594767
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-inducible factor 1-mediated characteristic features of cancer cells for tumor radioresistance.
Harada H
J Radiat Res; 2016 Aug; 57 Suppl 1(Suppl 1):i99-i105. PubMed ID: 26983985
[TBL] [Abstract][Full Text] [Related]
18. Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors.
Eckert F; Zwirner K; Boeke S; Thorwarth D; Zips D; Huber SM
Front Immunol; 2019; 10():407. PubMed ID: 30930892
[TBL] [Abstract][Full Text] [Related]
19. Radiation-responsive scintillating nanotheranostics for reduced hypoxic radioresistance under ROS/NO-mediated tumor microenvironment regulation.
Dou Y; Liu Y; Zhao F; Guo Y; Li X; Wu M; Chang J; Yu C
Theranostics; 2018; 8(21):5870-5889. PubMed ID: 30613268
[TBL] [Abstract][Full Text] [Related]
20. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy.
Meijer TW; Kaanders JH; Span PN; Bussink J
Clin Cancer Res; 2012 Oct; 18(20):5585-94. PubMed ID: 23071360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
